1. Scrip
  2. >>Therapy Areas

Interview: AC Immune CEO Reflects On Alzheimer's R&D Post-CREAD

 
• By John Davis

The recent failure of the CREAD studies to show a therapeutic effect for crenezumab in Alzheimer’s disease stunned developers. However, an ongoing clinical study of the MAb, and a series of other innovations being explored at Switzerland’s AC Immune, might still provide answers to this intractable condition.  

Pfeifer_Andrea
Andrea Pfeifer, CEO of AC Immune

The lack of efficacy of the investigational monoclonal antibody, crenezumab, at interim analysis in two Phase III studies, CREAD-1 and CREAD-2, in Alzheimer’s disease came as a shock to the drug’s originator, AC Immune SA. The Jan. 30, 2019 announcement by collaborator, Roche, “was a great disappointment,” says the Swiss biotech’s co-founder and CEO, Andrea Pfeifer.

“I have never seen a pivotal trial better prepared for than this,” said Pfeifer, in an interview with Scrip, in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapy Areas

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 
• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.